P0961 An inverse propensity score-weighted comparison between Vedolizumab, Ustekinumab, and Tofacitinib in ulcerative colitis patients refractory or intolerant to anti-TNF therapies

Post time Yesterday 23:07

journal：Journal of Crohn’s and Colitis

Authors：G Mocci; E V Savarino; L Bertin; W Elisei; B Barberio; G Maconi; A G Gravina; A Papa; F Scaldaferri; D G Ribaldone; L Bertani; G Bodini; A Tursi

Published date：2026-1-1

DOI：10.1093/ecco-jcc/jjaf231.1142

PDF link：https://academic.oup.com/ecco-jc ... 28/jjaf231.1142.pdf

Article link：https://doi.org/10.1093/ecco-jcc/jjaf231.1142

Article Source：Oxford University Press (OUP)。

Remark：

Post time Yesterday 23:08

: Waiting for confirmation
If the PDF has not been accepted after 72 hours, the system will automatically adopt it.

[Oxford] P0961 An inverse propensity score-weighted comparison between Vedolizumab, Ustekinumab, and Tofacitinib in ulcerative colitis patients refractory or intolerant to anti-TNF therapies

Viewed forums

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Oxford] P0961 An inverse propensity score-weighted comparison between Vedolizumab, Ustekinumab, and Tofacitinib in ulcerative colitis patients refractory or intolerant to anti-TNF therapies Copy